Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAOB | P27338 | 8/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL498377 | 0.88 | ALDH1A1 (0.56) | MAPTALDH1A1MAOBL3MBTL1KDM4E | |
| SCHEMBL22452587 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1MAOBTDP1TSHR | |
| SCHEMBL2560961 | 0.83 | ALDH1A1 (0.56) | MAPTALDH1A1MAOBMEN1KMT2A | |
| SCHEMBL12012132 | 0.83 | TDP1 (0.54) | MAPTALDH1A1MAOBTDP1TSHR | |
| SCHEMBL20968364 | 0.83 | MAOB (0.49) | MAPTALDH1A1MAOBTDP1TSHR | |
| SCHEMBL2566681 | 0.83 | MAOB (0.49) | MAPTALDH1A1MAOBTDP1TSHR | |
| SCHEMBL4743078 | 0.81 | TDP1 (0.56) | MAPTALDH1A1MAOBTDP1TSHR | |
| SCHEMBL18380932 | 0.81 | SCN5A (0.56) | MAPTALDH1A1L3MBTL1KDM4EMEN1 | |
| SCHEMBL17562366 | 0.79 | TDP1 (0.50) | MAPTALDH1A1MAOBTDP1TSHR | |
| SCHEMBL3885645 | 0.79 | HTT (0.47) | MAPTALDH1A1MAOBTDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| EP-2480532-B1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | claimed |
| US-8399676-B2 | Piperidine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | claimed |
| US-8258158-B2 | HSL inhibitors useful in the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2012-09-04 | — | — | US | claimed |
| EP-2480532-A1 | PIPERIDINE DERIVATIVES AND THEIR USE TO TREAT OBESITY, DIABETES, DYSLIPIDEMIA AND ATHEROSCLEROSIS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | claimed |
| EP-2475644-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2012-07-18 | — | — | EP | claimed |
| WO-2011029808-A1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | claimed |
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN-LA ROCHE, INC. | 2011-03-17 | — | — | US | claimed |
| US-3978049-A | Process for the preparation of hydrazine compounds | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1976-08-31 | — | — | US | claimed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| WO-2025054339-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS INHIBITORS OF KIT | ARCUS BIOSCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
| US-5236940-A | Administering for treatment of medical conditions associated with the effects of glutamate; glutamate-induced convulsions; schizophrenia; sleep disorders | RHONE-POULENC SANTE (FR) | 1993-08-17 | — | — | US | disclosed |
| US-5160487-A | Tetraarylbenzidine derivative as charge transport compound | HITACHI CHEMICAL COMPANY, LTD. (JP) | 1992-11-03 | — | — | US | disclosed |
| EP-0475676-A1 | Electrophotographic member | HITACHI CHEMICAL CO., LTD. (JP) | 1992-03-18 | — | — | EP | disclosed |
| US-5037991-A | Insecticides | SANDOZ LTD. (CH) | 1991-08-06 | — | — | US | disclosed |
| US-4968829-A | ANTHELMINTICS, PARASITICIDES, NEMATOCIDES | SANDOZ LTD. (CH) | 1990-11-06 | — | — | US | disclosed |
| US-3978049-A | Process for the preparation of hydrazine compounds | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065707-A1 | NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | LIPE, PNLIP, LPL | MAPT 4639/4885ALDH1A1 721/4885MAOB 1853/4885 |
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | MAPT 2291/4885ALDH1A1 2563/4885MAOB 542/4885 |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | MAPT 772/4885ALDH1A1 1563/4885MAOB 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.